Kwon Paul 4/A
4/A · Menlo Therapeutics Inc. · Filed Dec 16, 2019
Insider Transaction Report
Form 4/AAmended
Kwon Paul
Chief Scientific Officer
Transactions
- Tax Payment
Common Stock
2019-12-11$4.52/sh−27,766$125,502→ 52,534 total - Exercise/Conversion
Common stock
2019-12-11+80,300→ 80,300 total - Exercise/Conversion
Restricted Stock Units
2019-12-11−80,300→ 0 total→ Common Stock (80,300 underlying)
Footnotes (1)
- [F1]On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code.